K
Kenneth P. Nephew
Researcher at Indiana University
Publications - 284
Citations - 17018
Kenneth P. Nephew is an academic researcher from Indiana University. The author has contributed to research in topics: Ovarian cancer & DNA methylation. The author has an hindex of 66, co-authored 267 publications receiving 15106 citations. Previous affiliations of Kenneth P. Nephew include University of Tennessee Health Science Center & Indiana University – Purdue University Indianapolis.
Papers
More filters
Journal ArticleDOI
Molecular determinants of chemotherapy resistance in ovarian cancer
TL;DR: Molecular determinants of chemotherapy resistance in ovarian cancer include upregulation of antiapoptotic factors such as Bcl–2, Bcl-xL, MCL–1, survivin and downregulation of proapoptosis factors, which correlate with taxane and platinum-based cmotherapy resistance.
Proceedings ArticleDOI
BioVLAB-MMIA: A Reconfigurable Cloud Computing Environment for microRNA and mRNA Integrated Analysis
Hyungro Lee,Youngik Yang,Heejoon Chae,Seungyoon Nam,Donghoon Choi,Patanachai Tangchaisin,Chathura Herath,Suresh Marru,Kenneth P. Nephew,Sun Kim +9 more
TL;DR: This study has extending BioVLAB cloud workbench to develop an environment for the integrated analysis of micro RNA and mRNA expression data, namedBioVLAB-MMIA, which facilitates computations on the Amazon EC2 and S3 resources orchestrated by XBaya Workflow Suite.
Journal ArticleDOI
A Novel ALDH1A1 Inhibitor Blocks Platinum-Induced Senescence and Stemness in Ovarian Cancer
V Muralikrishnan,Fang Fang,Tyler C. Given,Ram Podicheti,Mikhail Chchterbinine,Shruthi Sriramkumar,Heather M. O'Hagan,Thomas D. Hurley,Kenneth P. Nephew +8 more
TL;DR: It is established that Aldehyde dehydrogenase 1A1 is essential for OCSCs survival and ALDH1A1 inhibition suppresses chemotherapy induced senescence and stemness and Targeting ALDH2A1 using small molecule inhibitors in combination with chemotherapy presents a promising strategy to prevent ovarian cancer recurrence and has potential for clinical translation.
Proceedings ArticleDOI
Abstract 2943: Novel combination therapy of DNMT inhibitor SGI-110 and PARP inhibitor BMN-673 (talazoparib) for BRCA-proficient ovarian cancer
TL;DR: Novel combination therapy of DNMT inhibitor SGI-110 and PARP inhibitor BMN-673 (talazoparib) for BRCA-proficient ovarian cancer and results in significant reductions in colony formation.
Proceedings ArticleDOI
Abstract 5189: The transcriptional regulation of the long non-coding RNA HOTAIR in ovarian cancer.
TL;DR: The transcriptional regulation of the long non-coding RNA HOTAIR in ovarian cancer was markedly induced in the cisplatin resistant cells and pharmacological inhibition of cMYC and NF-κB reduced HotaIR expression by 2-fold, and siRNA depletion of the NF-KKB p65 subunit or c MYC similarly reduced.